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Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors have been
explored as therapeutic agents for the treatment of hereditary
breast and ovarian cancers harboring mutations in BRCA1 or
BRCA2. In a new study, Inbar-Rozensal and colleagues show that
phenanthridine-derived PARP inhibitors promote cell cycle arrest
and cell death in breast cancer cells lacking BRCA1 and BRCA2
mutations and prevent the growth of tumors from xenografts of
these cells in immunocompromised mice. These results suggest a
potential broader utility of PARP-1 inhibitors in the treatment of
breast cancer, although further mechanistic studies are needed.
Recent studies have suggested that chemical inhibitors of
poly(ADP-ribose) polymerases (PARPs) might be effective as
therapeutic agents for the treatment of hereditary breast and
ovarian cancers harboring mutations in BRCA1 or BRCA2. In
a recent article from the Cohen-Armon group published in
Breast Cancer Research, Inbar-Rozensal and colleagues [1]
provide evidence that certain PARP inhibitors might also
inhibit the growth and promote the death of non-hereditary
breast cancer cells lacking mutations in BRCA1 or BRCA2.
These intriguing results might lead the way to new approaches
for treating a broad spectrum of breast cancer subtypes.
PARPs comprise a family of enzymes that catalyze the
polymerization of poly(ADP-ribose) chains on target proteins,
thereby modifying the activity of those proteins [2]. Nuclear
PARPs, such as PARP-1 and PARP-2, play key roles in
genome maintenance, cell death, inflammatory responses,
and the control of gene expression programs [2,3]. PARP
enzymatic activity increases in response to various cellular
stresses [2,3]. Given the central role of PARPs in vital cellular
processes as well as disease states, chemical inhibitors of
PARP have been explored as therapeutic agents for a wide
variety of diseases, including cancer [4,5].
Increasing evidence has linked PARP-1 to breast cancer. For
example, PARP-1-deficient mice exhibit increased sponta-
neous mammary carcinoma formation, the latency of which is
increased by mutations in p53 [6]. In addition, PARP activity
in human peripheral blood lymphocytes has been linked with
breast cancer [7] and low levels of PARP-1 gene expression
are associated with increased genetic instability in breast
cancer [8]. Furthermore, certain polymorphisms in PARP-1
may contribute to the development of breast cancer and
influence the effectiveness of hormone therapies [9]. Interest-
ingly, PARP inhibition (a) sensitizes p53-deficient breast
cancer cells to doxorubicin-induced apoptosis [10] and (b)
selectively kills breast cancer cells with hereditary inactivating
mutations in BRCA1 and  BRCA2, which encode proteins
critical for DNA repair by homologous recombination [5].
Finally, the PARP inhibitor, olaparib, has anti-tumor activity in
breast and ovarian cancers containing BRCA1 and BRCA2
mutations at safely administrable doses with minimal side
effects [11].
Building upon these exciting studies, Inbar-Rozensal and
colleagues [1] show that phenanthridine-derived PARP
inhibitors (for example, PJ-34) promote cell cycle arrest at
G2/M and cell death in breast cancer cell lines lacking
BRCA1 and  BRCA2 mutations (that is, MCF-7 and
MDA-MB-231). These effects were evident even after a short
(6-hour) treatment, and no recovery was observed after drug
removal. In contrast, although a transient cell cycle arrest was
also observed in normal breast epithelial cells (that is,
MCF-10A) and mouse embryo fibroblasts, recovery was
apparent within hours, even with continued drug exposure.
Furthermore, in immunocompromised nude mice, PJ-34 pre-
vented the growth of tumors from subcutaneous xenografts of
MCF-7 or MDA-MB-231 cells. From these studies, the authors
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conclude that phenanthridine-derived PARP inhibitors cause
cell cycle arrest and subsequent cell death in non-hereditary
breast cancer cells. Additional studies are needed, however,
to fully explore the activity of other structural classes of PARP
inhibitors. If these results translate into similar effects in
clinical studies, this would truly be a remarkable finding with
great therapeutic potential.
As with any promising initial study, many questions remain,
especially regarding the mechanism of action. Based on the
previous results with the BRCA1/2-deficent cells, the
assumption is that the ultimate target of the PARP inhibition
is a DNA repair pathway. Although MCF-7 and MDA-MB-231
cells are apparently wild-type for BRCA1 and BRCA2, they
may harbor mutations in genes encoding other DNA repair
and checkpoint proteins (for example, Rad51 and Chk1/2)
that could render them sensitive to PARP inhibitors.
Importantly, nuclear PARPs, such as PARP-1 and PARP-2,
also play key roles in gene regulation [2,3], so transcriptional
effects cannot be ruled out as the cause of PARP inhibitor
sensitivity. Experiments with depletion of specific PARPs will
help to determine the relevant targets.
Inbar-Rozensal and colleagues suggest a possible mecha-
nism underlying G2/M arrest by the PARP inhibitors through
signal transduction pathways involving cell cycle proteins (for
example, p21, cyclins, and cdc2) and extracellular signal-
regulated kinase (ERK)-dependent kinase cascades. This is a
reasonable hypothesis given the involvement of these
pathways in cell cycle progression and proliferation in a
variety of cancers, but additional experimental support is
needed. The Cohen-Armon group [12] previously demon-
strated that a signaling pathway involving ERK2 can support
sustained DNA-independent activation of PARP-1, which is
tied to signal-dependent chromatin modulation and gene
regulation.
Interestingly, PARP-1 expression levels are increased in
triple-negative breast cancer (that is, those that do not
express estrogen receptor [ER], progesterone receptor [PR],
and the human epidermal growth factor receptor HER2 [13]).
Although MCF-7 cells and MDA-MB-231 cells differ in their
expression of ER and PR (that is, MCF-7 cells express both
ER and PR whereas MDA-MB-231 cells do not), neither cell
line expresses HER2 [14]. HER2 is a cell membrane receptor
tyrosine kinase involved in signaling pathways leading to cell
proliferation, including those mediated by ERKs [15].
Functional connections between HER2, ERKs, and PARP-1
might play a role in determining the sensitivity of breast
cancer subtypes to PARP inhibitors. Comparing the effects of
phenanthridine-derived PARP inhibitors in MCF-7 and MDA-
MB-231 cells with forced expression of HER2 would be
informative in this regard.
In summary, the intriguing results of Inbar-Rozensal and
colleagues point to a broader utility of PARP inhibitors in
the treatment of breast cancer beyond hereditary BRCA1-
and BRCA2-deficient types. Further mechanistic studies are
needed, however, to understand the full spectrum of breast
cancer types for which chemical inhibition of PARPs might be
therapeutically beneficial. In addition, clinical studies will be
required to assess the efficacy in situ. Nonetheless, this
study deserves attention and should stimulate much-needed
further research in this area.
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